Community-viable screening for ASD in 9-month-old infants using quantitative eye-tracking assays of social visual engagement

项目总结 该项目是对NIMH RFA-MH-19-120号召开发和验证新筛查的响应 方法自闭症谱系障碍(ASD)可用于婴儿期(0-12个月)。我们将部署一支 经济高效的高通量方法，利用基于性能的、客观的、高度定量的眼睛- 社会视觉参与的跟踪分析--婴儿在视觉上探索、参与并最终 学习并适应他们周围的世界-通过独立的移动眼球跟踪数据收集 设备，在我们的实验室创建(马库斯自闭症中心调查设备，MAC-ID)。我们会收集眼睛- 跟踪来自N=2,000名9个月大婴儿的人口样本的跟踪数据 他们在9个月的健康儿童探视时采取了照护措施。这些婴儿将从9点开始进行纵向跟踪。 直至26个月，以完成一系列顺序筛查和临床确诊程序 旨在最大限度地提高敏感性，并实现ASD与非ASD的临床医生最佳估计诊断任务 ASD和受影响的[包括ASD和非ASD发育迟缓]与未受影响的对照。我们将测量 9个月大时基于眼球跟踪的筛查相对于临床医生最佳估计诊断的准确性 24个月(初步分析)，我们将在9个月时测量眼球跟踪分析之间的维度一致性 与社会残疾、语言能力和非语言认知能力的结果水平相关的月份(次要 分析)。我们的首要目标是开发能够发挥作用的高质量、客观、基于性能的工具 作为筛查自闭症和其他可操作的发育迟缓的有效和社区可行的手段 在婴儿期，最终促进更好地获得早期干预并从中受益。

PROJECT SUMMARY This project is in response to NIMH RFA-MH-19-120 calling for the development and validation of new screening methods for autism spectrum disorder (ASD) that can be used in infancy (0-12 months of age). We will deploy a cost-effective, high-throughput methodology utilizing performance-based, objective, and highly quantitative eye- tracking assays of social visual engagement—the way in which infants visually explore, engage, and ultimately learn from and adapt to their surrounding world—collected on a standalone, mobile eye-tracking data collection device, created in our lab (the Marcus Autism Center Investigational Device, MAC-ID). We will collect eye- tracking data from a population-based sample of N=2,000 9-month-old infants recruited consecutively in primary care practices at the time of their 9-month well-child visits. These infants will be followed longitudinally from 9 until 26 months for completion of a series of sequential screening and clinical ascertainment procedures designed to maximize sensitivity and achieve clinician-best-estimate diagnostic assignments of ASD vs. non- ASD and Affected [including ASD and non-ASD developmental delays] vs. Unaffected. We will measure the accuracy of eye-tracking-based screening at the age of 9 months relative to clinician best estimate diagnosis at 24 months (primary analysis), and we will measure dimensional agreement between eye-tracking assays at 9 months relative to outcome levels of social disability, verbal ability, and nonverbal cognitive ability (secondary analyses). Our overarching goal is to develop high-quality, objective, performance-based tools that can function as an effective and community-viable means of screening for ASD and other actionable developmental delays in infancy, to ultimately facilitate improved access to and benefit from early intervention.